Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma

Matteo Costacurta; Stephin J Vervoort; Simon J Hogg; Benjamin P Martin; Ricky W Johnstone; Jake Shortt

doi:10.3324/haematol.2020.265611

Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma

Haematologica. 2021 Jul 1;106(7):2013-2017. doi: 10.3324/haematol.2020.265611.

Authors

Matteo Costacurta¹, Stephin J Vervoort¹, Simon J Hogg¹, Benjamin P Martin¹, Ricky W Johnstone², Jake Shortt³

Affiliations

¹ Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne.
² Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne. ricky.johnstone@petermac.org.
³ Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville; Monash Haematology, Monash Health, Clayton; Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, Clayton. jake.shortt@monash.edu.

Abstract

Not available.

Publication types

Letter

MeSH terms

Clustered Regularly Interspaced Short Palindromic Repeats
Humans
Immunologic Factors
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics

Substances

Immunologic Factors

Grants and funding

Funding: JS is supported by an Australian Medical Research Future Fund Next Generation Clinician Researcher Fellowship; this research was funded by NHMRC project Ggrant 1127387; RWJ was supported by the Cancer Council Victoria, National Health and Medical Research Council of Australia (NHMRC), and The Kids’ Cancer Project; The Victorian Center for Functional Gnomics, the Molecular Genomics Core and the Flow Cytometry Core Facilities at the Peter MacCallum Cancer Center provided excellent technical support; The Peter MacCallum Foundation and Australian Cancer Research Foundation provide generous support for equipment and core facilities.